Midatech Pharma Signs Licensing Pact With Novartis
June 07 2017 - 4:14AM
Dow Jones News
LONDON--Pharmaceutical company Midatech Pharma PLC (MTPH.LN)
said Wednesday that it has signed a global licensing agreement with
Novartis AG (NOVN.EB) for the oncology compound panobinostat.
The company intends to develop panobinostat for the treatment of
brain tumor.
Shares at 0741 GMT trading 4.4% higher at 108 pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
June 07, 2017 03:59 ET (07:59 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024